Earlier this year I wrote about all the things that Treace is doing right here – Stepping into the future: How Treace Medical Concepts is revolutionizing F&A surgery with a relentless culture.
After the stock correction, many ortho friends have asked me to comment about Treace Medical Concepts. So here you go. (Disclaimer).
The Treace fundamentals are best in class. A quick look at the Q3 2023 numbers.
1/ Treace is the fastest growing public traded ortho company. Period.
2/ This is not a small business anymore. Treace has a 200M+ run rate.
3/ Treace has strong gross margins >80%.
4/ Treace is growing top line revenue at 36% YTD.
5/ Treace has war chest of cash for future growth and potential acquisitions.
6/ Treace has a chance to reach positive EBITDA in 2024.
1/ The Street got hooked on the stellar growth in the 45-65% range, and when Q3 this year reported 23% growth the Street put Treace in the penalty box temporarily. See annual growth rates below.
2/ The market is really skittish and most ortho company stock prices are down over the last 12 months.